Aducanumab for alzheimer disease

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Trial registered. A trial in people is registered. As of 19 Nov 2026, from 4 registered trials.

Why this status

  1. 19 Jul 2011: Trial registered, NCT01397539

The trials

NCT01397539: Single Ascending Dose Study of BIIB037 in Participants With Alzheimer's Disease

State
Completed
Phase
Phase 1
People
53 taking part
Started
Jun 2011
Primary completion
Aug 2013
Arms
BIIB037
Results
None posted
  1. 19 Jul 2011: Trial registered

NCT03639987: A Study of Aducanumab in Participants With Mild Cognitive Impairment Due to Alzheimer's Disease or With Mild Alzheimer's Disease Dementia to Evaluate the Safety of Continued Dosing in Participants With Asymptomatic Amyloid-Related Imaging Abnormalities

State
Stopped early
Phase
Phase 2
People
52 taking part
Started
20 Dec 2018
Primary completion
30 Jul 2019
Arms
Group 2
Results
Posted on the registry
  1. 21 Aug 2018: Trial registered
  2. 20 Dec 2018: Trial started
  3. 30 Jul 2019: Trial terminated
  4. 16 Sep 2021: Trial results posted

NCT04241068: A Study to Evaluate Safety and Tolerability of Aducanumab in Participants With Alzheimer's Disease Who Had Previously Participated in the Aducanumab Studies 221AD103, 221AD301, 221AD302 and 221AD205

State
Stopped early
Phase
Phase 3
People
1,696 taking part
Started
2 Mar 2020
Primary completion
22 Jul 2024
Arms
Aducanumab
Results
Posted on the registry
  1. 27 Jan 2020: Trial registered
  2. 2 Mar 2020: Trial started
  3. 22 Jul 2024: Trial terminated
  4. 21 Feb 2025: Trial results posted

NCT05310071: A Study to Verify the Clinical Benefit of Aducanumab in Participants With Early Alzheimer's Disease

State
Stopped early
Phase
Phase 3
People
1,027 taking part
Started
2 Jun 2022
Primary completion
12 Aug 2024
Arms
Aducanumab
Results
Posted on the registry
  1. 4 Apr 2022: Trial registered
  2. 2 Jun 2022: Trial started
  3. 12 Aug 2024: Trial terminated
  4. 23 Apr 2025: Trial results posted

How the status changed

  1. 19 Nov 2026: First set: Trial registered

About the treatment

Kind of treatment: Drug.

Also known as Aducanumab (BIIB037).

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.